Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for the growth of lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and/or bad,

Trial Details

NCT ID
NCT04085315
Phase
PHASE1
Sponsor
Collin Blakely
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Osimertinib
  • Alisertib
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Patients must have histologically confirmed stage IV non-small cell lung cancer.
  • Male or female patients \>=18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Documented activating EGFR mutation (Exon 19 deletion, Exon 19 insertion, E709K, G719X, S768I, V769L, T790M, L833F, L833V, V834L, H835L, L858R, A85…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →